A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
复制标题
DOI：
10.1016/j.jtho.2015.12.097
复制
发表时间：
2016-05-01
影响因子：
20.4
通讯作者：
Shim, Hyo Sup
中科院分区：
文献类型：
--
作者：
Cha, Yoon Jin;Cho, Byoung Chul;Shim, Hyo Sup
组织学变化可能涉及抗癌药物的耐药性。据报道，EGFR 突变型肺腺癌患者在接受 EGFR 酪氨酸激酶抑制剂治疗后转化为小细胞肺癌 (SCLC)。在此，我们报告一例 ALK 重排肺腺癌，其组织学类似 SCLC，位于对克唑替尼治疗耐药的腹部转移结节中。 (C) 2015 年国际肺癌研究协会。由爱思唯尔公司出版。保留所有权利。
Histologic changes can be involved in resistance to anticancer drugs. Transformation to small cell lung carcinoma (SCLC) following treatment with EGFR tyrosine kinase inhibitors has been reported in patients with EGFR-mutant lung adenocarcinoma. Herein, we report a case of ALK-rearranged lung adenocarcinoma with SCLC-like histology in a metastatic abdominal nodule that was resistant to crizotinib therapy. (C) 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.